Cangene (FRA:YGE) Additional Paid-In Capital : €37.81 Mil(As of Oct. 2013)

View and export this data going back to . Start your Free Trial

What is Cangene Additional Paid-In Capital?

Cangene's quarterly additional paid-in capital increased from Apr. 2013 (€0.46 Mil) to Jul. 2013 (€39.34 Mil) but then stayed the same from Jul. 2013 (€39.34 Mil) to Oct. 2013 (€37.81 Mil).

Cangene's annual additional paid-in capital increased from Jul. 2011 (€35.65 Mil) to Jul. 2012 (€41.76 Mil) but then declined from Jul. 2012 (€41.76 Mil) to Jul. 2013 (€39.34 Mil).

Cangene Additional Paid-In Capital Historical Data

The historical data trend for Cangene's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cangene Additional Paid-In Capital Chart

Cangene Annual Data

Trend

Jul04

Jul05

Jul06

Jul07

Jul08

Jul09

Jul10

Jul11

Jul12

Jul13

Additional Paid-In Capital

Get a 7-Day Free Trial

45.44

40.38

35.65

41.76

39.34

Cangene Quarterly Data
	Jan09	Apr09	Jul09	Oct09	Jan10	Apr10	Jul10	Oct10	Jan11	Apr11	Jul11	Oct11	Jan12	Apr12	Jul12	Oct12	Jan13	Apr13	Jul13	Oct13
Additional Paid-In Capital	Get a 7-Day Free Trial															39.60	0.41	0.46	39.34	37.81

Cangene Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Cangene Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Cangene's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Cangene (FRA:YGE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cangene Corporation (FRA:YGE) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.cangene.com

Cangene Corporation is a fully integrated developer and manufacturer of immune therapeutics, primarily targeting infectious disease, hematology, transplantation and biodefense applications. The company manages its business and evaluate performance based on two operating segments: biopharmaceutical operations and contract services. Revenues are generated from product sales, and contract manufacturing and contract-R&D services.

Cangene (FRA:YGE) Headlines

No Headlines